by GlobeNewsWire | Apr 13, 2016 | Globe Newswire
First biotechnology company to ever receive Vision of Hope Award PRINCETON, N.J., April 13, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, and the Sarcoma Foundation of America,...
by GlobeNewsWire | Apr 5, 2016 | Globe Newswire
Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort Part B Combination with 51 Patients to Begin Mid-Year PRINCETON, N.J., April 05, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer...
by GlobeNewsWire | Mar 29, 2016 | Globe Newswire
Study Commences Second Dose-Escalation Cohort 90-Patient Phase II Combination Trial in Cervical and Head and Neck Cancer to Begin Mid-Year PRINCETON, N.J., March 29, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company...
by GlobeNewsWire | Mar 23, 2016 | Globe Newswire
PRINCETON, N.J., March 23, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer...
by GlobeNewsWire | Mar 23, 2016 | Globe Newswire
PRINCETON, N.J., March 23, 2016 (GLOBE NEWSWIRE) — Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the company will host a Research Reception at the American Association for Cancer...